Mode
Text Size
Log in / Sign up
Early Phase 1 N=20 Randomized Triple-blind Basic Science

Influence of Medication on Functional Connectivity

Prescription Drug Abuse (Not Dependent)

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcome: Primary: Change in Functional Connectivity Following Oxycodone Administration — 2.66; 4.55; .99; 1.60 z-score

Study Design & Population

Study type
Interventional
Phase
Early Phase 1
Interventions
Oxycodone Medication First (Drug); Placebo First (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Yale University
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Functional Connectivity Following Oxycodone Administration
2.66; 4.55; .99; 1.60

Summary

This study will assess the effects of acute low-dose opioid administration on functional neuroimaging measures in healthy individuals

Eligibility Criteria

Inclusion Criteria

  • males or females, ages 18-30
  • for women of a child-bearing age, acceptable birth control methods or a negative pregnancy test prior to MRI scanning
  • ability to provide written, informed consent
  • eligibility and willingness to participate in fMRI scanning and to receive oxycodone
  • normal weight, as indicated by a body mass index (BMI) between 18.5 to 25

Exclusion Criteria

  • current DSM-5 Axis I disorder
  • any psychotropic medication or medication known to interfere with metabolism of opioids
  • medical contraindication to participate in study activities (acute low-dose opioid admin) as determined by study physician
  • known family history (first-degree relative) of opioid-use disorder or alcohol-use disorder
  • not eligible for MRI scanning
  • positive drug screen
  • recent (past 6 months) medical or non-medical opioid-use
  • current or previous chronic pain disorder
  • significant lifetime use of prescription opioids (>7 days of consecutive medical use or nonmedical use on more than 5 occasions)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03612713). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search